Author Archives: Natalie Themm
Intermountain Health Opens New Outpatient Surgery Center on TOSH Campus in Murray
Intermountain Health Opens New Outpatient Surgery Center on TOSH Campus in Murray
CancerVAX Reports Positive Progress on Kids Cancer Immunotherapy Treatment
UCLA research team has successfully created 7 pre-clinical monoclonal antibody candidates for targeting Ewing sarcoma
FDA Issues Final Guidance on Content of Premarket Submissions for Device Software Functions
On June 13, the U.S. Food and Drug Administration (FDA) issued the final guidance: Content of Premarket Submissions for Device Software Functions. The final guidance provides information regarding the recommended documentation sponsors should include in premarket submissions for the FDA’s evaluation of the safety and effectiveness of device software functions. The guidance replaces the FDA’s […]
Recursion’s Phase 2 Trial for the Treatment of Cerebral Cavernous Malformation has Fully Enrolled
Recursion’s small molecule is the first therapeutic candidate to be advanced to an industry-sponsored Phase 2 clinical trial for cerebral cavernous malformation (CCM). CCM is a devastating neurovascular disease with approximately 360,000 symptomatic patients in the United States and EU5.
Myriad Genetics Announces Research Collaboration to use Minimal Residual Disease Testing Platform
Myriad to support MD Anderson researchers studying metastatic renal cell carcinoma treatment selection and response
Vistim Labs Closes First Round of Funding
Vistim Labs Closes First Round of Funding
Culmination Bio and Cofactor Genomics Leverage Largest Biobank in the U.S. for PREDAPT Precision Medicine Clinical Trial
Respective leaders in healthcare innovation and RNA diagnostics team up to identify patients who will benefit from immunotherapy
NexEos Bio Names Dawn Rubel as President, Research and Development
NexEos Bio today announced that Dawn Rubel has joined the Company as President, Research and Development.
NUSANO TO PRESENT PRODUCTION CAPABILITIES TO EUROPEAN RADIOPHARMACEUTICALS WORKING GROUP
PROPRIETARY ION SOURCE AND BEAM TECHNOLOGY CAPABLE OF PRODUCING APPROXIMATELY 10 TIMES THE CURRENT GLOBAL SUPPLY OF ASTATINE-211
Thermo Fisher Scientific Opens Cell Therapy Facility at University of California, San Francisco, to Accelerate Development of Breakthrough Therapies
Thermo Fisher Scientific Opens Cell Therapy Facility at UCSF to Accelerate Development of Breakthrough Therapies
Intermountain Health Launches Culmination Bio
Intermountain Health announced the launch of Culmination Bio, a biotech company developing an exclusive, anonymized, and de-identified intelligence platform.
Still on the Hill…
BioUtah continues to monitor issues of importance to our industry and engage with legislators on Utah’s Capitol Hill.
